PCSK9 inhibition in patients with heart transplantation: A case series

P. B. Sandesara
D. Dhindsa
B. Hirsh, Zucker School of Medicine at Hofstra/Northwell
M. Jokhadar
R. T. Cole
L. S. Sperling

Abstract

© 2019 National Lipid Association PCSK9 inhibitors are potent low-density lipoprotein cholesterol–lowering medications. There is a lack of data regarding safety and efficacy of PCSK9 inhibitors in cardiac transplant patients. In this case series, we provide data supporting the low-density lipoprotein–lowering efficacy and short-term safety of PCSK9 inhibitors in three cardiac transplant patients.